Aignostics is an international, interdisciplinary team powering the next generation of precision medicine by advancing the fields of AI and pathology. Founded as a spin-off from Charité Berlin and the Berlin Institute of Health in 2020, the company builds on years of research from Charité, TU Berlin, and Fraunhofer HHI. With offices in Berlin and New York, Aignostics offers rigorously developed products and custom services geared toward precision medicine.

Our mission is to transform drug development and improve patient outcomes with AI that delivers novel insights for precision medicine. We have access to multimodal pathology data from over 30 million patients at leading university hospitals and laboratories. Our team includes data scientists, machine learning engineers, pathologists, and biologists who provide expert oversight across all products and services.

We offer foundation models for pathology workflows, including embedding generation and customization. Our flagship product, Atlas H&E-TME, is a comprehensive tumor microenvironment profiling application. Custom services span from target and biomarker discovery to translational research and digital diagnostics for clinical tool development.

Aignostics values fairness, honesty, humility, and teamwork. The company fosters a diverse and collaborative environment with a strong commitment to innovation in AI and medicine. We embrace diversity, equity, and inclusion and prioritize a healthy work-life balance to drive high performance.